Biogen stock heads into the open after a 1.6 percent decline
Published on 09/22/2026 at 05:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Biogen stock closed at USD 215.50 on Nasdaq on September 18, 2026, down 1.62 percent from the prior session, according to exchange data cited in an overview by MarketBeat. The shares ended the day near the upper end of their 52-week range between USD 135.39 and USD 225.80, implying a market capitalization of roughly USD 31.84 billion as of that date per the same data.
September 18, 2026 in numbers
Biogen Inc. (ISIN US09062X1037, Nasdaq: BIIB) finished regular trading on Nasdaq at USD 215.50 on September 18, 2026, compared with a previous close that left the session showing a 1.62 percent decline, based on figures cited by MarketBeat. Intraday trading saw a low of USD 215.41 and a high of USD 219.91, with volume around 2,630,000 shares in the same session per exchange data summarized by MarketBeat. The 52-week range for Biogen shares stood between USD 135.39 and USD 225.80 on September 18, 2026, leaving the latest close close to the upper band of that corridor and reflecting a market capitalization near USD 31.84 billion as of the same date, according to MarketBeat data. In comparison, the broader Dow Jones Industrial Average and other major United States equity benchmarks registered gains on September 21, 2026 after an earlier period of weakness, as reported by CNBC.
Events around Biogen today
World Alzheimer’s Day on September 21, 2026 kept major Alzheimer’s drug developers in focus, with Biogen highlighted among key names in a sector overview by Zacks, underscoring continuing attention to the company’s neurology pipeline as markets move into today’s session. Broader market sentiment heading into today has been shaped by a rebound in major United States equity indices and ongoing interest in health care and biotechnology stocks, according to a recent market review from Zacks, which could influence trading conditions for Biogen shares today.
